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Abstract
Purposes (1) Determine the association of multiple can-
cers with smoking, focusing on cancers with an uncertain
association; and (2) illustrate quantitative bias analysis as
applied to registry data, to adjust for misclassification of
smoking and residual confounding by alcohol and obesity.
Methods New Zealand 1981 and 1996 censuses, includ-
ing smoking questions, were linked to cancer registry data
giving 14.8 million person-years of follow-up. Rate ratios
(RR) for current versus never smokers, adjusting for age,
sex, ethnicity and socioeconomic factors were calculated
and then subjected to quantitative bias analysis.
Results RR estimates for lung, larynx (including ear and
nasosinus), and bladder cancers adjusted for measured con-
founders and exposure misclassification were 9.28 (95 %
uncertainty interval 8.31–10.4), 6.14 (4.55–8.30), and 2.22
(1.94–2.55), respectively. Moderate associations were found
for cervical (1.82; 1.51–2.20), kidney (1.29; 1.07–1.56),
liver cancer (1.75; 1.37–2.24; European only), esophageal
(2.14; 1.73–2.65), oropharyngeal (2.30; 1.94–2.72), pan-
creatic (1.68; 1.44–1.96), and stomach cancers (1.42;
1.22–1.66). Protective associations were found for endo-
metrial (0.67; 0.56–0.79) and melanoma (0.72; 0.65–0.81),
and borderline association for thyroid (0.76; 0.58–1.00),
colon (0.89; 0.81–0.98), and CML (0.66; 0.44–0.99).
Remaining cancers had near null associations. Adjustment
for residual confounding suggested little impact, except the
RRs for endometrial, kidney, and esophageal cancers were
slightly increased, and the oropharyngeal and liver (Euro-
pean/other) RRs were decreased.
Conclusions Our large study confirms the strong association
of smoking with many cancers and strengthens the evidence for
protective associations with thyroid cancer and melanoma.
With large data sets, considering and adjusting for residual
systematic error is as important as quantifying random error.
Keywords Smoking  Cancer incidence  Quantitative
bias analysis  Epidemiological methods
Introduction
The International Agency for Research on Cancer (IARC)
and US Surgeon General (US-SG) now both recognize at
least 12 cancers for which active smoking is a causal factor
[1, 2]. The grouping of cancers by level of evidence and
strength of association with smoking is shown in Table 1.
More latterly, cancers with modest causal associations have
been identified (e.g., nasal cavities and sinuses, squamous
cell carcinoma of the cervix, renal cell carcinoma, and
stomach cancer; Table 1). Only endometrial cancer in
postmenopausal women clearly has a reduced rate among
smokers. Consistently, null associations have been found
for some common cancers (category 5 in Table 1). But
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there remain a number of cancers for which there is
uncertainty about any causal association with tobacco
smoking (category 4 in Table 1). The substantive focus of
this paper is on these latter ‘uncertain’ category 4 cancers.
Increasingly, epidemiological studies use large databases,
often assembled through record linkage. Cancer registry
studies—linked to mortality data—are often of this type.
Record linkage beyond routine health data sets can enrich the
data and extend possible analyses. In this paper, we use
cancer registry data linked to national census data that hap-
pens to include smoking questions [3]. The periodic inclu-
sion of a smoking question in New Zealand censuses (1976,
1981, 1996, 2006, and 2013) and subsequent linkage with
health data allows rich epidemiological analyses (e.g.,
mortality and prevalence analyses we have previously pub-
lished [4–8]). Linkage of 5 years of cancer registry data back
to each of the 1981 and 1996 censuses creates some of the
largest cohort studies of smoking and cancer incidence
enabling a precise (i.e., narrow confidence interval) deter-
mination of relative risks of multiple cancers with smoking.
But—in common with many registry and linkage studies—
exposure assessment is not ideal (i.e., two simple questions
on smoking status only) and data on some key potential
confounders are missing (e.g., neither the NZ census nor
cancer registry collects data on obesity or alcohol con-
sumption). It is, however, possible to undertake quantitative
bias analyses (QBA), in this case to adjust for possible
misclassification bias of smoking and residual confounding
by obesity and alcohol. (It is also possible that smoking
contributes to lower BMI, and thus, adjusting for BMI is a
form of overcontrol for confounding. However, for the
purposes of this paper, we assume that the obesity is pre-
dominantly a confounder in that there are common causes of
both smoking and increased BMI, or—expressed in directed
acyclic graph terminology—BMI is on a backdoor path from
smoking to cancer incidence.) Such QBA methods have
existed in the epidemiological repertoire since 1959 [9], but
are surprisingly infrequently used. Lash, Greenland, and
colleagues have recently strongly argued for their wider
application in epidemiology [10–12], noting that refusing to
undertake QBA is tantamount to saying there is no remaining
systematic error in one’s study. Thus, a second purpose of
this paper is to demonstrate relatively simple QBA methods
as applied to linked cancer registry data.
Brief overview of smoking–cancer associations
The association of breast cancer with smoking has been
debated for sometime, with studies producing inconsistent
findings [1, 2, 13–16]. For instance, while a major meta-
analysis concluded there was little or no effect of smoking
[13], two recent large cohort studies have found a modest
Table 1 Association of current smoking with cancers, and date of
first pronouncement of any causal relationship by either the Interna-
tional Agency for Research on Cancer (IARC) or US Surgeon General
(US-SG)
Category
Cancer site
Strength of
associationa
Date of IARC or US-SG
pronouncement, and commentsb
1. Causality established: moderate to strong association
Bladder mm IARC 1986 (bladder, ureter, and
renal pelvis)
Larynx, nasal
cavity, ear, and
sinus
Larynx mmm US-SG 1964
Nasal cavity/
sinus
mm IARC 2004
Lip, mouth, and
pharynx
Oral cavity mm US-SG 1979
Pharynx mmm IARC 1986
Lung, bronchus,
and trachea
mmm US-SG 1964
Esophagus mm US-SG 1979 (extended to
adenocarcinoma US-SG and
IARC 2004)
2. Causality established: weak to moderate association
Cervix m US-SG 2004 and IARC 2004
(SCC only [1, 48])
Kidney (except
renal pelvis)
m IARC 2004 and US-SG 2004
Pancreas m IARC 1986
Stomach m IARC 2004 and US-SG 2004
3. Causality likely: protective association
Endometrium
(postmenopausal)
. US-SG 2004
4. Association and causality uncertain
Breast (female) 0 to m IARC 2012: evidence of a small
association. US-SG 2004:
evidence suggestive of no
causal association
Colorectum 0 to m IARC 2012: evidence supports a
causal association (although
may be limited to certain
subtypes). US-SG 2004:
evidence suggestive, but not
sufficient
Gallbladder and
bile ducts
– [As a rare cancer, lack of
statistical power means any
association is ‘unknown’ more
than ‘likely null.’]
Leukemia 0 IARC 2004 (myeloid leukemia);
US-SG 2004 (acute myeloid
leukemia). [However, null in
meta-analysis [47] of IARC
data (1.09, 95 % CI 0.70–1.70),
hence we include it in
‘causality uncertain.’]
Myeloid
leukemia
0 to m
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positive (increased risk) association of smoking with breast
cancer [15, 16]. The latest IARC report (2012) identifies a
consistent but weak positive association (RRs 1.1–1.3) [17].
The 2012 IARC report also states that current data
support a causal relationship between smoking and colo-
rectal cancer, although this may be limited to specific
subtypes of colorectal cancer [17]. However, recent meta-
analyses have reported weak positive associations with
RRs of 1.07 (0.99–1.16) [18] and 1.17 (0.97–1.40) [19].
The association of smoking with leukemias and lym-
phomas is difficult to determine because they are hetero-
geneous groups of diseases, but there is some (inconsistent)
evidence suggesting that the risk of follicular lymphoma
may be increased [1, 20, 21]. IARC and the US-SG rec-
ognize a casual association of smoking with myeloid leu-
kemias [1, 2, 22–24]. However, a meta-analysis of the
IARC data for myeloid leukemia did not find a statistically
significant increase in risk [25].
Regarding ovarian cancer, three recent meta-analyses
reported RRs of about two or more for mucinous ovarian
tumors (10–20 % of all ovarian cancer cases) [26–28].
A causal association between smoking and mucinous, but
not other types of, ovarian cancer has been identified by
IARC [17].
A causal association of smoking with liver cancer is
recognized by IARC [1], but not yet by the US-SG [2]. The
strong correlation of smoking with other causes of liver
cancer makes it difficult to confidently rule out residual
confounding. Liver cancer is usually caused by chronic
infection with hepatitis B or C viruses (HBV/HCV); HBV
is particularly important in New Zealand among Ma¯ori and
Pacific people [29]. Alcohol and other risk factors also
make a contribution. A meta-analysis that carefully con-
sidered the confounding influence of alcohol, HBV, and
HCV found RRs of 1.4–1.5 for liver cancer for current
versus never smokers [30].
Melanoma is thought to have either no association or a
possible negative association with smoking [1, 31, 32].
There is also some evidence of a negative association for
thyroid cancer [33].
Methods
Data set
The 1981 and 1996 New Zealand censuses included
questions on smoking. These two censuses and New Zea-
land Cancer Registry (NZCR) records for 1981–1986 and
1996–2001, respectively, were anonymously and probabi-
listically linked using geocodes, sex, date of birth, ethnic-
ity, and country of birth (further details of methods are
available elsewhere: www.uow.otago.ac.nz/cancertrends-
info.html and [34]). The proportion of people with cancer
who were successfully linked to a census record was 73 %
for the 1981–1986 cohort and 80 % for the 1996–2001
cohort; accordingly, we calculated inverse probability of
linkage weights for strata based on age, sex, ethnicity,
residential mobility of the neighborhood, time since cen-
sus, small area deprivation, cancer diagnosis, and region of
the country. Assuming that there is negligible linkage
variation by smoking status within strata of these covari-
ates, these weights protect against linkage bias in final-
weighted analyses.
Observations were included for all person-years of fol-
low-up for current and never smokers aged 25 years and
older. (Ex-smokers are excluded from the main analyses;
however, results are available in Web Table 1 and Web
Table 2).
Table 1 Continued
Category
Cancer site
Strength of
associationa
Date of IARC or US-SG
pronouncement, and commentsb
Liver 0 to m IARC 2004: evidence sufficient to
infer a causal association. US-SG
2004: evidence suggestive, but
not sufficient
Melanoma 0 to .
Ovarian IARC 2012: evidence sufficient to
infer a causal association for
mucinous ovarian cancer
Mucinous
tumors
mm
Other tumor
types
0
Thyroid 0 to . IARC 2012: evidence suggestive of
an inverse association
5. Evidence suggestive of no association
Brain 0
Hodgkin’s 0
Myeloma 0
Non-Hodgkin’s
lymphoma
(NHL)
0 [However, there has been a
suggested association with
follicular NHL.]
Prostate 0
Testes 0
Comments in square brackets are those of the authors of this paper,
not IARC or US-SG
SCC squamous cell carcinoma
a mmm RR [ 5; mm RR 2 to B5; m RR 1 to B2; ‘‘0’’ is evidence
suggestive of no causal association (i.e., RR = 1); ‘‘–’’ is evidence
inconclusive or inadequate; . significant protective relationship.
Relative risk (or odds ratio) used in theses groupings are as summa-
rized by the IARC and US-SG reports [1, 2, 47, 49] and other meta-
analyses [13, 18, 19, 21, 27, 30, 33, 43, 48, 50, 51]
b US-SG reports relating to smoking and health (1964, 1979, 1982,
1990, 2004) are available at http://www.surgeongeneral.gov/library/
reports/index.html, and IARC Monographs relating to smoking (vol-
ume 38: 1986; volume 83: 2004 and; volume 100E; 2012) are
available at http://monographs.iarc.fr/
Cancer Causes Control
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Variables
The 1981 census included the following question ‘‘Tick the
box which best describes your current cigarette smoking,’’
with three options: Never smoked cigarettes at all, or never
smoked them regularly; do not smoke cigarettes now, but
used to smoke them regularly (1 or more per day); and cur-
rently smoke cigarettes regularly (1 or more per day). The
1996 census used a two-step approach: (1) ‘‘Do you smoke
cigarettes regularly (that is, one or more per day)?’’ (Count
only tobacco cigarettes. Don’t count pipes, cigars, or ciga-
rillos); and for those answering ‘‘no,’’ (2) ‘‘Have you ever
been a regular smoker of one or more cigarettes per day?’’
Socio-demographic census data collected included age,
sex, ethnicity, marital status, and multiple measures of
socioeconomic position, including household income;
highest educational qualification; household car access and
housing tenure (both markers of asset wealth, and the latter
also access to resources); and neighborhood deprivation
(calculated for neighborhoods of about 100 people, using
nine census variables [35]).
The outcome was a first cancer registered with the NZCR
during the follow-up periods, excluding basal and squamous
cell carcinomas of the skin and other in situ cancers. Cancers
prior to 2000 were forward mapped from ICD-9 to ICD-10
codes. Site-specific analyses were conducted for adult cancer
groupings (see Table 2 for groupings and ICD-10 codes). It
was not possible to reliably identify the morphological types
such as mucinous ovarian cancer.
Cohort analysis
Census respondents developing cancer were censored at the
date of diagnosis. Unfortunately, due to privacy and
logistical reasons, it was not possible to censor for death
among people not developing a cancer or emigration out of
New Zealand (estimated at less than 0.02 % per year;
www.stats.govt.nz).
Age- and ethnicity-standardized (WHO world standard,
further disaggregated by NZ ethnic distribution) incidence
rates and rate ratios of cancer according to smoking status
were calculated separately by sex and cohort. Three Pois-
son regression analyses were conducted for each cancer,
for sexes and cohorts combined. First, a baseline regression
model was run on the full data set, adjusting for sex, age,
ethnicity, and cohort. Second, a model adjusting for the
same variables was run on data restricted to those
respondents with complete data on all socio-demographic
factors. (About 26 % of respondents had missing data on
one or more of the socioeconomic factors, usually house-
hold income which was classified as missing if any adult in
the household had missing data due to either refusal or
being away from their usual residence on census night.)
Comparing the second to baseline models allowed an
assessment of selection bias, or at least that selection bias
due to missing socioeconomic data. Third, a Poisson
regression model adjusting additionally for socioeconomic
factors was run on this restricted data set. Analyses by
ethnic grouping were conducted for liver cancer only, due
to the marked variation in the causal role of hepatitis B
virus by ethnicity [29].
We selected ‘best’ rate ratio (RR) estimates from
regression models 1 and 3 as follows. First, if there was
negligible confounding by socioeconomic factors (which we
conservatively defined as\3 % shift in the RR from model 2
to 3), then the best estimate was that from model 1. Second, if
there was some confounding (i.e., C3 % shift in RR from
model 2 to 3) and negligible selection bias (\3 % shift in RR
from model 1 to 2), then the best estimate was that from
model 3. Third, the remaining cancers had some evidence of
both selection bias and confounding, and no direct ‘best’
estimate was available from our regression models. How-
ever, assuming that the observed amount of confounding
moving from models 2 to 3 would have applied to the model
1 estimate if we actually had socioeconomic data on all
census respondents, we were able to indirectly estimate what
the ‘true’ RR estimate might have been. For example, if
confounder adjustment resulted in a 15 % reduction in the
RR from models 2 to 3, then our ‘derived’ estimate would be
85 % of the model 1 RR. (A worked example of these esti-
mations is given in Box 1.)
Quantitative bias analysis: exposure misclassification
and residual confounding
The census smoking variable is a crude measure, meaning
our results were prone to exposure misclassification bias.
We undertook quantitative bias analyses [10, 11] in pur-
pose built Excel spread sheets using Monte Carlo simula-
tion with Ersatz software (www.epigear.com). Details are
provided in Web Appendices 1 and 2; briefly, a mis-
classification matrix of actual by self-reported smoking
status was generated based on Heller et al. [36] and other
studies and then modeled as a Dirichlet distribution applied
to a subset of the crude data (45–64 and 65–84 year olds of
European/other ethnicity from the 1996–2001 cohort, to
avoid confounding by age or ethnicity) to generate cor-
rected risk ratios. There was a near perfect linear associa-
tion of the log of these adjusted RR estimates with the log
of the crude RRs (Fig. 1), and we used this association to
adjust all smoking–cancer RRs (Table 3).
The census does not include variables on potential
confounders such as obesity and alcohol. We undertook
bias analyses for cancers with known associations with
either obesity or alcohol (detail in Web Appendix 1).
Briefly, we used: (1) distributions of obesity and total
Cancer Causes Control
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alcohol consumption by smoking status among restricted
age groups for European/other from the 2002/03 New
Zealand Health Survey [37]; (2) the relative risk associa-
tions of obesity [38] and alcohol [39–42] with various
cancers, and (3) uncertainty modeled with Dirichlet
(prevalence data) and log normal distributions (relative
risks).
Results
Smoking status was missing for 1.7 and 4.7 % of the 1981
and 1996 cohorts, respectively, giving 14.8 million person-
years in total. Current smokers accounted for 36 % of
person-years (41 % of the 1981–1986 cohort, and 31 % of
the 1996–2001 cohort).
Table 2 shows the number of cancers for current and
never smokers, and the age and ethnicity-standardized
incidence rate ratios (SRRs). The SRRs were greater than
2.0, as expected, for larynx/ear/nasosinus and lung cancers.
Table 3 shows the RRs from Poisson regression models.
Shifts in the RRs from model 1 to model 2 reflect selection
bias arising from using the restricted data set of only
respondents with complete data on all socio-demographic
factors. Selection bias was notable for gallbladder and bile
duct cancer (20 % increase in RR) and larynx/ear/nasosi-
nus (16 % increase), and for liver (14 % increase; Ma¯ori/
Pacific/Asian only) and lung/trachea/bronchi cancers
(10 % increase).
Shifts in RRs from model 2 to model 3 (additionally
adjusting for socioeconomic factors) reflect confounding.
Strong confounding was apparent for melanoma (a 12 %
increase in RR from 0.65 to 0.73), consistent with mela-
noma being more common among higher socioeconomic
groups who are less likely to smoke. Rate ratios also
increased modestly after adjustment for breast cancer,
follicular lymphoma and prostate cancer. Modest 5–9 %
reductions in the rate ratios after adjustment were evident
for cervical, larynx/ear/nasosinus and liver cancers.
The third to last column of Table 3 presents ‘best’
empirical RR estimates from either model 1 or model 3
and ‘derived’ estimates for seven cancer groupings that
had evidence of both confounding and selection biases (see
‘‘Methods’’ for details).
We also further adjusted for misclassification bias of the
smoking exposure (details in Web Appendix 1). Briefly,
we found that this adjustment had a negligible impact for
our best estimate relative risks up to about 1.25, but for
higher RRs, our best estimates increasingly underestimated
the exposure misclassification-adjusted estimates. Notably,
the association of the crude and exposure misclassification-
adjusted risk ratios for 36 sex by age by cancer strata
from the 1996–2001 cohort was near perfectly linear on theT
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log–log scale (Fig. 1). We used the equation for this slope
and the finding that the uncertainty interval on the log scale
was 8 % wider than the random error confidence interval,
to calculate exposure misclassification-adjusted relative
risks and uncertainty intervals (UI) for all cancers as shown
in the second to last column of Table 3. The misclassifi-
cation exposure-adjusted RRs were[10 % higher than the
original estimates for bladder, esophagus, and oropharynx
cancer and[20 % higher for lung and larynx/ear/nasosinus
cancer.
Finally, we also explored likely residual confounding by
alcohol and smoking for the 1996–2001 cohort for selected
cancers (details in Web Appendix 1). The impact of
residual confounding was usually negligible, with overes-
timation of associations due to obesity (less common
among smokers) often partly offset by underestimation due
to confounding by alcohol (higher among smokers). Net
effects of this confounding are depicted in the final column
of Table 3, suggesting that our best estimate exposure
misclassification-adjusted RRs still underestimate the RR
for endometrial, kidney, and esophageal cancer by up to
0.20. Conversely, we likely overestimate oropharynx
association by as much as 0.4. But with the exception of
endometrial cancer, these cancers still have moderate to
strong RR associations with smoking.
Substantively, the following patterns are evident in
Table 3. Lung and larynx/ear/nasosinus cancers had
markedly increased (RR [ 6) incidence among current
smokers. Bladder and esophagus have a clearly greater than
doubling of incidence, and five cancers have a 20 % to
twofold increased rate among current smokers with
uncertainty intervals clearly excluding the null: cervix,
kidney, oropharynx, pancreas, and stomach. Conversely,
four cancers have at least a 20 % lower rate among current
smokers with uncertainty intervals excluding the null:
endometrial (empirical best estimates of 0.67; 95 % UI
0.56–0.79, and for 50 ? years 0.60; 0.50–0.73; but due to
residual confounding by obesity, the true RRs might be
about 0.08 higher), CML (0.66; 0.44–0.99), melanoma
(0.72; 0.65–0.81), and thyroid cancer (0.76; 0.58–1.00).
Eleven cancers had best RR estimates within 15 % of
the null and with uncertainty intervals including the null:
brain, breast, rectum, gallbladder and bile duct, Hodgkin’s,
AML, CLL (and non-AML combined), myeloma, NHL
(and follicular lymphoma), ovary, and testicular.
Colon cancer had a best empirical estimate RR of 0.89,
with the uncertainty interval just excluding the null
(0.81–0.98). However, our confounding bias analyses
suggested that we were still slightly underestimating the
RR, possibly to the extent that a corrected uncertainty
interval would include the null.
The liver RRs varied markedly by ethnic grouping, with
a strong 1.75 (1.37–2.24) association among European/
other (probably slightly overestimated due to residual
confounding by alcohol) but a null association among
Ma¯ori/Pacific/Asian combined (0.80; 0.53–1.20).
Box 1 Demonstration of how the ‘best’ RR estimate was calculated
for cancer of the larynx, ear, and nasosinus (as in Table 3)
Model 1 gives the RR for all current smokers with adjustment for
sex, age, ethnicity, and cohort (i.e., 5.38)
In Model 2, we restrict our population to those smokers with
complete data on socioeconomic status (SES) variables (i.e., car
access, education, house tenure, household equivalized income,
and neighborhood deprivation) and run the same analysis as in
Model 1 (i.e., not yet adjusted for SES). Thus, the difference in
RR compared with Model 1 (from 5.38 to 6.23, or 16 %) is due
to selection bias from exclusion of those smokers with missing
data
In Model 3, we use the same population as for Model 2, but now
adjust for SES. Thus, the change in RR compared with Model 2
(from 6.23 to 5.83, or a 6 % reduction) represents the effect of
confounding by SES
To estimate the best RR to this point, we assume the 6 % reduction
due to confounding by SES would have applied to the Model 1
RR of 5.38 (i.e., before selection bias was introduced); this gives
a best RR to this point of 5.03. We assume the standard error of
ln[RR] from Model 3 applies to this RR of 5.03, giving a 95 %
confidence interval of 3.88–6.53
Next, we adjust the RR further for misclassification bias of the
smoking exposure. We use the observed association between
RRs with and without adjustment of misclassification bias (as
shown in Fig. 1); specifically, we use the regression equation for
ln[smoking misclassification-adjusted RR] (y axis) on ln[crude
RR] (x axis). Thus, our RR with adjustment for misclassification
of smoking exposure (shown in the second to last, or ‘‘exposure
misclassification’’ column, of Table 3) is:
Exp(1:1075  ln[5:03 þ 0:0264Þ ¼ 6:14:
In calculating confidence intervals around this RR, we need to take
account of uncertainty in the bias parameters themselves.
Uncertainty in misclassification of smoking exposure is captured
in the Dirichlet distribution for the misclassification matrix (see
Web Appendix 1). Across all our quantitative bias analyses
(QBA) for exposure misclassification in Web Appendix 1, we
found that the total uncertainty interval was on average 8 %
greater than the random error-only 95 % confidence interval.
Accordingly, we inflate the confidence intervals around the
previous RR estimate by 8 % to give a ‘total uncertainty
interval’ of 4.55–8.30
The final step is to quantify any ‘net’ residual confounding by
alcohol and obesity, based on a simple averaging of the impact
of these confounding QBA (as explained in Web Appendix 1).
These further suggested corrections are shown as possible ranges
of absolute adjustment to the RR in the final column of Table 3.
In the case of larynx, ear, and nasosinus cancer, our assessment
was that no additional adjustment was necessary
The RR estimates for cancer of the larynx, ear, and nasosinus
cancer showed a fairly substantial degree of selection bias and
confounding. For other cancers, the above adjustments were
applied only if the shift in RRs between Models 1 and 2, and
Models 2 and 3, was greater than 3 % (see ‘‘Methods’’ for
further details)
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Model 3 regressions were rerun to test for any signifi-
cant interactions by sex and by cohort (Web Table 3). By
sex, there was evidence of a stronger protective association
of smoking for melanoma among males (RR 0.62;
0.56–0.69) compared to females (RR 0.84; 0.76–0.93).
This stronger protective effect for males was evident in
both the 1981–1986 and 1996–2001 cohorts (SRRs in
Table 2). There was some suggestion that if there is any
protective association for leukemia and its subtypes, it is
only present in females. By cohort, there was a tendency
for RRs to be further away from the null (be it less than or
greater than 1.0) in the 1996–2001 cohort compared to the
1981–1986 cohort (Web Table 3).
Discussion
This study largely agrees with IARC or US-SG reports
regarding associations of smoking with various cancers
[1, 2]. Figure 2 plots the best empirical estimates from this
study (i.e., second to last column of Table 3, plus addi-
tional adjustments for likely confounding by alcohol and
obesity for kidney, liver (European/other only), esopha-
geal, and oropharyngeal cancers) and recent meta-analyses
(where they exist). The concordance is good. Considering
category 1 and 2 cancers (positive causal association with
smoking, Table 1), our estimates all have the lower 95 %
confidence or uncertainty limits greater than 1.0. Our study
also finds a strong protective association for endometrial
cancer consistent with a previous meta-analysis [43]. We
also find a protective association for thyroid cancer (RR
0.76; 95 % UI 0.58–1.00) adding weight to Mack et al.’s
[33] pooled analysis that found an OR of 0.6 (0.6–0.7). One
possible mechanism for both of these protective relation-
ships is the anti-estrogenic effects of smoking [44].
The category 4 ‘‘causality uncertain’’ cancers are best
interpreted after a discussion of this study’s main strengths
and limitations: measurement error of the smoking expo-
sure, and potential residual confounding.
The census smoking question that classified smoking
status for our study is simple and does not capture intensity or
duration. There were also likely to be some current smokers
(inadvertently) reporting themselves as never smokers (or
ex-smokers and hence excluded from our study), and vice
versa some never smokers reporting themselves as current
smokers. However, a key strength of our study is the inclu-
sion of QBA which (assuming a valid bias model and
parameters as detailed in Web Appendices 1 and 2) suggests
negligible impact of exposure misclassification for most
cancers and allows us to estimate exposure misclassification-
adjusted estimates for all cancers (Table 3). While we have
adjusted for bias from misclassification of the simple
smoking question, further measurement error against a
construct such as ‘pack-years’ was not possible; we assume
that such correction would further strengthen the association
for cancers already linked with smoking while having min-
imal effect on findings for other cancers. That said, we
believe that misclassification bias is unlikely to be a major
limitation for assessing ‘uncertain’ or marginal smoking–
cancer associations in this study given the close agreement
between our misclassification-corrected RR for cancer of the
lung, trachea, and bronchus and that of Gandini et al.’s [25]
meta-analysis of IARC data (Fig. 2), and the observation that
misclassification of smoking status has little impact on RRs
close to 1.0 (Fig. 1).
Our exploratory confounder bias adjustments provide
considerable reassurance that residual confounding by
alcohol and obesity is unlikely—except for our study
underestimating the association of endometrial, kidney,
and esophageal cancer with smoking and overestimating
the association of liver (European/other only) and oro-
pharyngeal cancer. But none of these four instances alter
conclusions: Smoking will still be protective for endome-
trial cancer and increase risks for the other four.
Fig. 1 Plot of log of smoking
misclassification-adjusted risk
ratio by log of crude risk ratio,
for 36 sex by age (45–64 and
65–84 year olds; European/
other only) by cancer strata
from the 1996–2001 cohort.
Lung cancer among 65–84-
year-old males excluded as
outlier. See Web Appendix 1 for
further details
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There was a tendency in our study for rate ratios to be
further from the null in 1996–2001 than 1981–1986
(Table 2 and Web Table 3). This may be consistent with
the 1996–2001 results reflecting a more mature smoking
epidemic (especially for a long time-lag process such as
cancer etiology) and less passive smoking risk in the never
smokers, resulting in stronger rate ratios.
Returning to the substantive interpretation of our study
findings for the category 4 ‘‘causality uncertain’’ cancers, one
remaining source of bias deserves attention. The apparent
negative association between smoking and prostate cancer
may reflect more health conscious never-smokers being more
likely to undergo prostate-specific antigen testing resulting in
higher apparent incidence among this group, rather than a
genuine protective effect. In contrast, it seems unlikely that
the observed protective association of smoking for melanoma
is purely due to bias. A protective association for melanoma
with RRs of 0.5–0.8 has been previously reported (although
often with wide confidence levels including the null) [1, 31,
32, 45]. Curiously, the one other study to report results by sex
also found a strong protective association among males,
consistent with our study (Web Table 3). It is possible that the
apparent protective effect is due to confounding by sunlight
exposure, but this would require a strong association between
low sunlight exposure and smoking within strata of socio-
economic factors that we have already adjusted for. Such an
association seems unlikely, and we know of no evidence for
this in the NZ population. Thus, we would recommend re-
categorizing melanoma as ‘‘Causality likely: protective
association.’’ It is possible that because smoking has an
Fig. 2 Forest plot of incidence
rate ratios from: current
CancerTrends study {best
estimates from Table 3 [The
best estimates from this study
are those in the second to last
column of Table 3 (i.e.,
misclassification bias adjusted),
with the following four
modification for likely residual
confounding: addition of 0.08 to
the endometrial cancer 25? RR
giving 0.75 (0.63–0.89);
addition of 0.08 to the kidney
cancer RR giving 1.37
(1.13–1.65); addition of 0.15 to
the esophageal cancer RR
giving 2.29 (1.85–2.83);
subtraction of 0.25 from the
oropharynx RR giving 2.05
(1.73–2.43); subtraction of 0.05
from European/other liver
cancer RR giving 1.70
(1.33–2.17)]}; solid black error
bars, with ‘multiplication sign’
central estimate]; IARC data
meta-analysis [25] (red bars
with vertical dash central
estimate); and miscellaneous
meta-analyses (see text and
footnotes to Table 1 for
references) red bars with
‘circle’ central estimate. AML
acute myeloid leukemia, CML
chronic myeloid leukemia, CLL
chronic lymphocytic leukemia,
NHL non-Hodgkin’s lymphoma.
(Color figure online)
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immunosuppressive effect [46], it protects melanocytes from
UV radiation-induced inflammatory damage [32].
Smoking is recognized as a causal factor for myeloid
leukemia by both IARC [1] and the US-SG [2], and the
latter limits this to acute disease (AML). However, we did
not find smoking to be significantly associated with AML,
consistent with a recent meta-analysis for all myeloid
leukemia (RR 1.09; CI 0.70–1.70) [47]. The apparently
protective association for CML (best empirical estimate
0.66; 95 % UI 0.44–0.99) found in our study is inconsistent
with the majority of international research, which suggest a
null or possibly positive association [23, 24]. Ours may
well have been a chance finding (consistent with an upper
uncertainty limit of 0.99 and measurement of multiple
associations).
Regarding liver cancer, our study discloses an important
interactionofsmokingwithethnicity (Table 3). It seems likely
that among Ma¯ori/Pacific/Asian where hepatitis B is involved
in the etiology of over 80 % of cases (compared to 6 % or less
among European/other) [29], smoking is not a necessary
causal cofactor with hepatitis B. However, our finding of an
approximately 70 % increased risk among European/other
smokers is consistent with the RR of 1.56 (95 % CI 1.29–1.87)
from the meta-analysis of IARC data [47].
Finally, our study finds no compelling evidence of a link
between smoking and breast, rectal, colon, gallbladder and
bile duct, myeloma, brain, Hodgkin’s, NHL, ovary and
testicular cancers, and follicular lymphoma. Regarding
colon, rectal, and breast cancers, there is some evidence that
cancer risk increases with duration of smoking [10, 17, 19].
However, an increased risk with increased duration of
smoking is also the case for other cancers that we do detect
moderate or strong associations with, and most people ini-
tiate smoking by age 20. Our study cannot separately detect
long-run from short-run causation, but it does seem unlikely
that our study would produce null findings for colorectal
and breast cancer—but not other cancers—if this hypothesis
was true.
Conclusion
Our large study with measured and unmeasured confounder
adjustment, and smoking misclassification adjustment,
confirms the strong association of smoking with many
cancers. However, our study also strengthens the evidence
for protective associations of smoking for thyroid cancer
and melanoma. We find no compelling association of
smoking with breast and colorectal cancer. Contrary to
recent statements, we find no association of smoking with
AML. Our study also demonstrates how QBA can be
applied to registry data and to strengthening causal infer-
ence in analyses on such data.
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